摘要
目的:观察非布司他联合阿托伐他汀钙治疗高脂血症合并高尿酸血症患者的效果。方法:选取2020年2月至2023年3月该院收治的120例高脂血症合并高尿酸血症患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各60例。对照组予以阿托伐他汀钙治疗,观察组在对照组基础上联合非布司他治疗。比较两组临床疗效、治疗前后血脂指标[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)]水平、血尿酸水平、血管内皮功能指标[可溶性细胞间黏附分子-1(sICAM-1)、内皮素-1(ET-1)]水平和不良反应发生率。结果:观察组治疗总有效率为93.33%(56/60),高于对照组的80.00%(48/60),差异有统计学意义(P<0.05);治疗后,观察组TG、TC、LDL-C、血尿酸水平均低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05);观察组sICAM-1、ET-1水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:非布司他联合阿托伐他汀钙治疗高脂血症合并高尿酸血症患者可提高治疗总有效率,改善血脂指标水平,降低血尿酸和血管内皮功能指标水平,效果优于单纯阿托伐他汀钙治疗。
Objective:To observe effects of Febuxostat combined with Atorvastatin calcium in treatment of patients with hyperlipidemia and hyperuricemia.Methods:A prospective study was conducted on 120 patients with hyperlipidemia and hyperuricemia admitted to the hospital from February 2020 to March 2023.According to the random number table method,they were divided into control group and observation group,60 cases in each group.The control group was treated with Atorvastatin calcium,while the observation group was treated with Febuxostat on the basis of that of the control group.The clinical efficacy,the blood lipid indexes[total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C)]levels,the serum uric acid level,the vascular endothelial function indexes[soluble intercellular adhesion molecule-1(sICAM-1),endothelin-1(ET-1)]levels before and after the treatment,and the incidence of adverse reactions during treatment were compared between the two groups.Results:The total effective rate of the observation group was 93.33%(56/60),which was higher than 80.00%(48/60)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of TG,TC,LDL-C and uric acid in the observation group were lower than those in the control group,the level of HDL-C was higher than that in the control group,and the differences were statistically significant(P<0.05).The levels of sICAM-1 and ET-1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Febuxostat combined with Atorvastatin calcium in the treatment of the patients with hyperlipidemia and hyperuricemia can improve the total effective rate of treatment,improve the levels of blood lipid indexes,and reduce the levels of serum uric acid and vascular endothelial function indexes.Moreover,it is superior to single Atorvastatin calcium treatment.
作者
万晓娟
WAN Xiaojuan(Department of Endocrinology and Nephrology of Yellow River Central Hospital of Yellow River Conservancy Commission,Zhengzhou 450003 Henan,China)
出处
《中国民康医学》
2024年第5期38-40,44,共4页
Medical Journal of Chinese People’s Health
关键词
高脂血症
高尿酸血症
阿托伐他汀钙
非布司他
血脂
血管内皮
不良反应
Hyperlipidemia
Hyperuricemia
Atorvastatin calcium
Febuxostat
Blood lipid
Vascular endothelium
Adverse reaction
